Oak Longevity vs LTTL: Prices, shipping, and pharmacy checks
Quick verdict: Oak Longevity is positioned for cost-conscious patients seeking compounded semaglutide from $133/month and tirzepatide from $199/month with no subscription; LTTL emphasizes pharmacy verification and an introductory credit of up to $140 off your first month. This Oak Longevity vs LTTL comparison highlights pricing, pharmacy verification, subscription terms, clinical review and regulatory notes so you can decide quickly.
See Oak Longevity semaglutide from $133/mo
Head-to-head: five key differences between Oak Longevity and LTTL
This Oak Longevity vs LTTL comparison focuses on the most distinctive, supported differences: starting price and pricing model, subscription and billing, pharmacy preparation and testing, clinical review flow, and regulatory notes about compounded medications.
1. Starting price and pricing model
Oak Longevity lists semaglutide from $133/month and tirzepatide from $199/month, explicitly noting one flat price for all dosages. LTTL’s captured evidence does not provide a single starting price per medication but highlights promotional pricing with up to $140 off your first month and mentions prices like $249 and $129 in captured text. The sources therefore present Oak as the clearer low-cost, flat-price option, while LTTL emphasizes an introductory credit and variable price points.
Check LTTL offers with up to $140 off first month
2. Subscriptions, billing and renewals
Oak states there are no subscriptions or membership fees and that billing is monthly on a non-recurring basis; three-month prescriptions are billed upfront and no refunds are available after physician approval and once medication has shipped. LTTL’s captured content does not include verified subscription or renewal terms; the source cautions that pricing, eligibility, pharmacy, state coverage and renewal terms may change and advises confirming those details before enrollment.
3. Pharmacy prep and lab verification
Oak describes its medications as compounded and prepared by compounding pharmacies and includes a regulatory note that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. LTTL’s captured evidence specifically says medications are compounded by U.S.A. licensed pharmacies and prepared in a state-licensed pharmacy, independently verified in FDA registered labs, with confirmation every 3–6 months to stay within ± 10% of target strength. That difference highlights LTTL’s recorded emphasis on independent lab verification in the captured material.
4. Clinical review and access flow
Oak indicates the clinical review is asynchronous with no video call required: patients complete an online questionnaire and a licensed physician reviews the case; Oak also notes board-certified physicians in your state review every case and same-day approval is available for qualifying patients. LTTL’s captured details repeatedly state treatment is available only when a licensed clinician determines it is medically appropriate but do not provide the captured workflow specifics for synchronous or asynchronous review.
5. Regulatory note and suitability
Both sources include the regulatory caution that compounded medications are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Oak also notes patients with BMI below 20 do not qualify for GLP-1 treatment and elsewhere states not appropriate for patients under 18, pregnant, or nursing. LTTL’s captured material includes the same broad regulatory note and advises confirming eligibility and state availability before enrollment.
| Criteria | Oak Longevity | LTTL |
|---|---|---|
| Starting price | Semaglutide from $133/mo; tirzepatide from $199/mo | Promotional details: up to $140 off first month; various captured prices |
| Dosage pricing | One flat price covers all dosages | Captured text: “Same price, every dose” and other price points mentioned |
| Subscriptions | No subscriptions or membership fees; billed monthly non-recurring | Captured landing page did not verify subscription/renewal details; confirm before enrolling |
| Pharmacy and lab verification | Compounded by compounding pharmacies; regulatory note about compounded status | Prepared by state-licensed pharmacies; independently verified in FDA registered labs; confirmed every 3–6 months |
| Clinical review | Asynchronous clinical review; no video call required; board-certified physicians review cases | Treatment subject to licensed clinician determination; workflow specifics not captured |
Explore Oak Longevity pricing and free coaching
What this means for you
In short, Oak Longevity vs LTTL breaks down to a clearer low-cost, flat-price presentation from Oak with explicit no-subscription billing and asynchronous review, while LTTL’s captured evidence emphasizes pharmacy lab verification and an applied first-month credit of up to $140 but does not verify subscription terms in the captured material. Both note compounded medications are not FDA-approved and that treatment is available only when a licensed clinician determines it is medically appropriate.
Review LTTL pharmacy verification and offer details
Choose Oak Longevity if…
You are cost conscious and prefer a clear, low starting price with one flat price for all dosages, no subscriptions, free shipping and free health coaching, and you are comfortable with asynchronous clinician review. Oak is described as best for cost-conscious patients with uncomplicated health history who want the most affordable compounded GLP-1 online.
Choose LTTL if…
You want medication prepared by state-licensed pharmacies with independent verification in FDA registered labs and an applied introductory credit; confirm current pricing, eligibility, renewal terms and state availability before enrolling because those details may change.